Facial Injectable Market Trends

Global Facial Injectable Market Overview

Facial Injectable Market size worth USD 89.2 Billion at a CAGR 8.8% by 2032.The market for facial injectables is divided into goods with high-end and cutting-edge technology. The increase in the prevalence of chronic illness, the expanding use of self-injectable devices, and the growth of FDA approvals drive the market. In addition, there is a noticeable increase in the population of older adults. The younger generation is increasingly turning to the cosmetics business to seem young, along with the aging population acting as market drivers.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The facial injectables industry is segmented into premium and innovative products. The market is being driven by factors such as the rising incidence of chronic diseases, the popularity of self-injectable devices, and the expansion of FDA approvals. There is also a considerable boom in the number of people aged 65 and up. Market growth is being fueled by both the aging population and the younger generation's desire to fake youth using cosmetics.

The demand for face injectables has been on the rise in recent years, thanks to consumers' growing fixation on their appearance. Various beauty commercials run by key market participants have contributed to a greater public understanding of minimally invasive procedures, which in turn has fueled market growth. As a result, more people are interested in getting cosmetic operations done, with Botox being one of the most popular options.

Allergan, Sinclair Pharma, and Galderma are three of the most prominent companies in the injectable facial procedures market, and they treat a wide variety of skin conditions with their fillers, including wrinkles, pigmentation, lip plumping, scars, restoring facial fullness, and enhancing facial contours.

In January 2023, the long-awaited nationwide release of JUVÉDERM VOLUX XC was announced by Allergan Aesthetics, a division of AbbVie (NYSE: ABBV). Aesthetic establishments now offer the long-lasting hyaluronic acid (HA) filler to patients over the age of 21 who have experienced moderate to severe loss of jawline definition. The newest addition to the JUVÉDERM Collection, JUVÉDERM VOLUX XC, is a non-surgical, minimally invasive treatment alternative that requires almost no recovery time. Patients were very pleased with the results of treatment with JUVÉDERM VOLUX XC in a clinical trial. When it comes to dermal fillers, Americans like the JUVÉDERM Collection more than any other.

In March 2022 at AMWC 2022, Galderma released new clinical data about its dermal filler portfolio, high patient satisfaction for the said products, and this also includes collagen biostimulators and liquid neuromodulators. Galderma presented new scientific data on its range of hyaluronic acid-based dermal fillers – the first-ever Liquid Neuromodulator and an innovative Collagen Biostimulator at The Aesthetic & Anti-Aging Medicine World Congress 2022 in Monaco.

Facial Injectable Market Trends

• Strong Surge of Facial Injectable Adoption to boost the market growth

Consumers' increasing emphasis on looks has fuelled the market for facial injectables in recent years. Another factor driving market expansion is the rise in awareness of minimally invasive procedures due to different beauty advertisements run by major market participants. Several adults are experiencing what is known as the "Zoom Boom," or an increase in self-awareness. Due to this, there is a higher demand for aesthetic procedures, with Botox being one of the most widely used procedures.

Due to the simplicity of healing while recuperating at home, patients are now choosing cosmetic procedures. As a result, the market experienced a surge during the epidemic, and this tendency is anticipated to continue. The demand for injectable facial procedures is anticipated to be driven by the presence of well-established key players like Allergan, Sinclair Pharma, and Galderma with a comprehensive injectable fillers portfolio treating a broad range of skin indications like wrinkles, pigmentation, lip plumping, scars, restoring facial fullness, as well as enhancing facial contours. The population's growing desire to seem youthful and aesthetically pleasing is anticipated to fuel the market during the projected period, along with rising face injectable effectiveness and approvals. 

Invasive surgeries are quickly being replaced with minimally invasive procedures. For instance, the American Society of Plastic Surgeons (ASPS) estimates that approximately 18 million minimally invasive and surgical cosmetic procedures, of which about 16 million were minimally invasive, were carried out in the U.S. in 2020. As a result, the market is expanding due to the rising popularity of minimally invasive operations and the accessibility of various treatment alternatives. The United States was ranked first globally in terms of non-surgical procedures conducted, according to the International Society of Aesthetic Plastic Surgery (ISAPS). Of these, injectables such as hyaluronic acid and botulinum toxin were among the most frequently used treatments.Therefore, the rising consumer base of the aging population will enhance the Facial Injectable market CAGR globally in recent years.

Both the awareness of visual appeal and disposable incomes have increased significantly globally. As a result, attitudes towards cosmetic procedures have changed as more people opt to enhance their physical features. While they are considered safer and necessitate little to no downtime, minimally invasive procedures like face injectables are becoming increasingly popular, contributing to the Facial Injectable market revenue.

Facial Injectable Market Segment Insights

Facial Injectable Application Insights

The Facial Injectable market segmentation based on application includes facial line correction treatment, face lifts, and lip treatments. The face lift segment held the majority share in 2022, contributing to around ~55-57% of the Facial Injectable market revenue. This expansion results from more people using facial injectables for aesthetic operations, including treating lip lines, facial wrinkles, and facial lines, to mention a few. The market is anticipated to increase due to rising disposable income and awareness of cosmetic procedures. Market expansion is anticipated to be aided by an increase in the usage of cosmetic injectables for parentheses lines, facial wrinkles, lip lines, lip augmentation, lip border restoration, perioral lines, and crow's feet lines.

August 2022:Through its Business Unit of Allergan Aesthetics, Allergan Healthcare India introduced Juvéderm VOLUX, an injectable implant designed to replenish and add volume to the face.

February 2021:Galderma's Restylane Defyne for Chin Augmentation was given FDA approval in the United States.

Figure 1: Facial Injectable Market, by Surgery, 2022 & 2030 (USD billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Facial Injectable End User Insights

Based on end user, the Facial Injectable market segmentation includes hospitals and specialty clinics, and spa & beauty clinics. The spa & beauty clinics dominated the market in 2022 and are projected to be the faster-growing segment during the forecast period, 2022-2030. Throughout the period under study, spa & beauty clinics are predicted to rule the market. Due to the prevalence of injectable face procedures performed in specialty clinics& beauty clinics, this end-user context is dominant. Many people choose to have these fillers placed in these areas because the treatments involve little to no downtime adding value to the market growth.

Facial Injectable Type Insights

The Facial Injectable market data has been bifurcated by type into botulinum toxin, hyaluronic acid, polymers, particles, and collagen. The hyaluronic acid segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. To delay the effects of aging, middle-aged women are increasingly choosing fillers and injectables, such as the well-known Botox. It is well renowned for retaining moisture in the skin, making it appear healthier. The critical moisture responsible for the plumpness of the facial skin is enhanced and maintained by the moisture-binding property of HA. Cosmetic-grade HA's low molecular weight makes it easier for the substance to deeply penetrate the epidermis, which further aids in the retention of water in the cells and the production of antioxidants that slow the aging process.In March 2023, FACE by Galderma, an augmented reality (AR) aesthetic visualization tool, was released by Galderma. This application helps aesthetic professionals and patients visualize the consequences of injectable treatments during the pre-treatment planning phase. This novel approach provides patients with a virtual "before and after" picture of their potential treatment outcomes, which can help allay their fears regarding injectable results. Galderma's injectable aesthetic solutions can now be virtually tried out and evaluated in an augmented reality setting. In April 2023, RELIFE, a division of the Menarini Group, the largest pharmaceutical company in Italy, will introduce a groundbreaking new line of face fillers called Definisse. Good volumizing capability and predictable, long-lasting, and safe outcomes can be obtained with the Definisse series of hyaluronic acid (HA) fillers thanks to its cutting-edge, stable and elastic 3D matrix produced utilizing groundbreaking 'EXcellent Three-dimensional Reticulation' (XTR) Technology. 

Facial Injectable Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America Facial Injectable market accounted for USD 7.3 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The huge senior population in the United States and Canada is responsible for this growth, which is expected to fuel the need for face injectables over the projected period. The American Society of Plastic Surgeons (ASPS) evaluated the rise in cosmetic surgery product rates between 2000 and 2018. It was noted that there was an 845 percent increase in the use of Botox injections. Hence, it is anticipated that North America will be a major source of revenue for facial injectables in the years to come.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: FACIAL INJECTABLE MARKET SHARE BY REGION 2022 (%) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Facial Injectable market accounts for the second-largest market share during the forecast period. The high volume of cosmetic operations performed in the area, such as botulinum toxin and other dermal fillers, is one of the factors contributing to the region's significant market share. Additionally, it is anticipated that new product releases would drive the market in the region in the region by important firms combined with high expenditure patterns. Further, the Germany Facial Injectable market held the largest market share, and the UK Facial Injectable market was the fastest growing market in the European region

The Asia-Pacific Facial Injectable Market is expected to grow at the fastest CAGR from 2022 to 2030. Countries like South Korea, Australia, and India support the region. In these developing nations, there is projected to be a growing emphasis on physical beauty, which will significantly impact the market for injectable facial treatments. Moreover, China Facial Injectable market held the largest market share, and the India Facial Injectable market was the fastest growing market in the Asia-Pacific region

For instance, the India Facial Injectable market will grow with a rapidly growing CAGR in Asia. A growing elderly population, increased awareness of aesthetic surgical procedures, technical improvements in cosmetic operations, the existence of important market competitors, and an increase in the demand for non-invasive aesthetic procedures are all contributing factors to the growth. Due to the growing focus on geriatric aesthetics within this age group, the demand for aesthetic fillers is anticipated to rise, driving the market's expansion in the Indian region.

Facial Injectable Key Market Players & Competitive Insights

Major market players invest heavily in their research and development departments to diversify their product portfolio to appeal to a wider consumer base. The market leaders focus on integrating strategic initiatives such as market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Also, prominent players in the Facial Injectable industry offer their products at a moderate price.

Market leaders in the Facial Injectable industry are considering investing in regional and local manufacturing units to reduce their operating costs further. The Facial Injectable market major player such as Eisai Co. Ltd (Japan), Antares Pharma (U.S.), AstraZeneca (U.K.), Becton Dickinson and Company (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), and Johnson and Johnson Services Inc. (U.S.), and others are working on expanding the market demand by investing in research and development activities.

With operations throughout 18 nations, Eli Lilly and Company is an American pharmaceutical firm with its main office in Indianapolis, Indiana. Over 125 nations sell its products. The business was established in 1876 and is named after Colonel Eli Lilly, a pharmacist, and American Civil War soldier. By 2022, Lilly was best known for its antipsychotic drug Zyprexa (olanzapine) and its clinical depression drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine), and Trulicity (dulaglutide), though its diabetes medications Humalog (insulin lispro) (1996, Trulicity (dulaglutide), and Trulicity (dulaglutide), will generate the majority of its revenue (2014). Among Lilly's accomplishments is becoming the first business to mass-produce the Jonas Salk-developed polio vaccine and insulin. It was among the first pharmaceutical businesses to use recombinant DNA to generate human insulin, notably Humulin.

Roche is the brand name for F. Hoffmann-La Roche AG, a healthcare conglomerate with two divisions: pharmaceuticals and diagnostics. Shares of Roche Holding AG, its holding company, are traded on the SIX Swiss Exchange. Basel is where the corporate headquarters are situated. Roche is the world's top supplier of cancer medicines and the fifth-largest pharmaceutical firm in revenue. The corporation owns a 100% stake in the American biotechnology firm Genentech, as well as 100% stakes in the Japanese biotechnology firm Chugai Pharmaceuticals and the American firms Ventana and Foundation Medicine. In the fiscal year 2020, Roche brought in 58.32 billion Swiss francs.

Key Companies in the Facial Injectable market include

• 
  

  Eisai Co. Ltd (Japan)

  
  


• 
  

  Antares Pharma (U.S.)

  
  


• 
  

  AstraZeneca (U.K.)

  
  


• 
  

  Becton Dickinson and Company (U.S.)

  
  


• 
  

  Eli Lilly and Company (U.S.)

  
  


• 
  

  F. Hoffmann-La Roche AG (Switzerland)

  
  


• 
  

  Johnson and Johnson Services Inc. (U.S.)

  
  


• 
  

  Mylan N. V. (U.S.)

  
  


• 
  

  Novartis AG (Switzerland)

  
  


• 
  

  Novo Nordisk (Denmark)

  
  


• 
  

  Pfizer Inc. (U.S.)

  
  


• 
  

  Sanofi (France)

  
  


• 
  

  Teva Pharmaceutical Industries Ltd. (Israel), among others

  
  

Facial Injectable Industry Developments

May 2024: Galderma introduced Restylane® VOLYME™, a hyaluronic acid injectable filler, to the Chinese market. The company is now launching its supplementary Shape Up Holistic Individualized Treatment (HIT™) in the country. This treatment specifically targets the aging problems that arise from the lack of structural support in the mid-face. Galderma's provision of these specific remedies for the mid-face area exemplifies their dedication to fulfilling the requirements of patients and injectors in China. 

Over the past ten years, China's aesthetics medicine market has had faster development than the worldwide market. Despite having relatively low market penetration, there is still considerable potential for future expansion. Restylane® VOLYME™ is created utilizing Galderma's exclusive OBT™* gel technology. It is designed to address the lack of volume or shape in the mid-face area by injecting it into the layers of skin between the subcutaneous and supraperiosteal layers. Two to three Hyaluronic acid fillers are commonly preferred by patients for enhancing the mid-face area and have demonstrated excellent patient satisfaction and enduring outcomes.4 Hyaluronic acid fillers rank in the top 10 best-selling aesthetics products in China.

May 2022: Pulse NeedleFree Systems, the primary provider of needle-free delivery technology to the animal health sector, unveils the inaugural range of disposable needle-free vaccination devices for livestock, a global first.  The Pulse FX product line provides pig producers with the advantages of needle-free technology, ensuring both the health and food safety of their products. This technology is easy to use and requires minimal setup, making it as convenient as traditional syringes and needles. Additionally, the cost of Pulse FX is similar to that of conventional syringes and needles. 

The Pulse FX is a non-adjustable gadget that does not necessitate any upkeep, repairs, or component substitution. The dose quantities available range from 0.2 ml to 2.0 ml, and there are options for both hand-held and hands-free stationary delivery. The FX model is highly suitable for field workers in demanding production environments, thanks to its sophisticated ergonomics and remarkably lightweight (500 gram) construction. Pulse products are extensively utilized by major meat producers in the United States and global markets. These products provide the administration of liquid medications through subcutaneous or intramuscular delivery, eliminating the need for intrusive and contaminated needles. The Pulse technology tackles important industrial goals related to animal welfare, food safety, biosecurity, and labor productivity.

December 2020:To provide DaxibotulinumtoxinA for Injection, Ajinomoto Bio-Pharma Services and Revance Therapeutics established a manufacturing arrangement.

February 2022:Being the first and only aesthetic injectable to address moderate to a severe loss of jawline contour, Merz Aesthetics introduced Radiesse (+).

Facial Injectable Market Segmentation

Facial Injectable Application Outlook (USD Billion, 2019-2030)

• 
  

  Facial Line Correction Treatment

  
  


• 
  

  Face Lift

  
  


• 
  

  Lip Treatments

  
  

Facial Injectable End User Outlook (USD Billion, 2019-2030)

• 
  

  Hospitals

  
  


• 
  

  Specialty Clinics and Spa & Beauty Clinic

  
  

Facial Injectable Type Outlook (USD Billion, 2019-2030)

• 
  

  Botulinum Toxin

  
  


• 
  

  Hyaluronic Acid

  
  


• 
  

  Polymers

  
  


• 
  

  Particles and Collagen

  
  

Facial Injectable Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  

• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America